Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials-Reference-Cited by-同舟云学术

Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials

Published:2010-02 Issue:2 Volume:20 Page:102-110
ISSN:0960-8966
Container-title:Neuromuscular Disorders
language:en
Short-container-title:Neuromuscular Disorders

Author:

Popplewell Linda J.,Adkin Carl,Arechavala-Gomeza Virginia,Aartsma-Rus Annemieke,de Winter Christa L.,Wilton Steve D.,Morgan Jennifer E.,Muntoni Francesco,Graham Ian R.,Dickson George

Publisher

Elsevier BV

Subject

Genetics (clinical),Neurology (clinical),Neurology,Pediatrics, Perinatology and Child Health

Reference31 articles.

1. Dystrophin: the protein product of the Duchenne muscular dystrophy locus;Hoffmann;Cell,1987

2. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus;Monaco;Genomics,1988

3. Genetic treatments in muscular dystrophies;Muntoni;Curr Opin Neurol,2007

4. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse;Mann;Proc Natl Acad Sci USA,2001

5. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients;Aartsma-Rus;Hum Mol Genet,2003

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Production of Duchenne muscular dystrophy cellular model using CRISPR-Cas9 exon deletion strategy;Molecular and Cellular Biochemistry;2023-06-08

2. Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype in vitro;Molecular Therapy - Nucleic Acids;2022-12

3. Antisense oligonucleotides targeting exon 11 are able to partially rescue the Neurofibromatosis Type 2 phenotype in vitro;2022-02-11

4. Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination;Pharmacology & Therapeutics;2022-02

5. Lessons learned from developing an oligonucleotide drug for a rare disease;RNA Therapeutics;2022